OLYSIO

Ülke: Yeni Zelanda

Dil: İngilizce

Kaynak: Medsafe (Medicines Safety Authority)

Aktif bileşen:

Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg

Mevcut itibaren:

Janssen-Cilag (New Zealand) Ltd

INN (International Adı):

Simeprevir sodium 154.4 mg (equivalent to simeprevir 150.0 mg)

Doz:

150 mg

Farmasötik formu:

Capsule

Kompozisyon:

Active: Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg Excipient: Colloidal silicon dioxide Croscarmellose sodium Gelatin Lactose monohydrate Magnesium stearate Opacode black S-1-277002 Sodium laurilsulfate

Reçete türü:

Prescription

Tarafından üretildi:

Janssen Pharmaceutica NV

Terapötik endikasyonlar:

Olysio is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 or genotype 4 infection, in combination with other medicinal products for the treatment of CHC infection.

Ürün özeti:

Package - Contents - Shelf Life: Blister pack, PVC-PE-PVDC blister & Al push-through foil - 7 capsules - 24 months from date of manufacture stored at or below 30°C protect from light - Blister pack, PVC-PE-PVDC blister & Al push-through foil - 28 capsules - 24 months from date of manufacture stored at or below 30°C protect from light

Yetkilendirme tarihi:

2013-09-02